Top Markets
#1 Akedo Akedo +57.36%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.30%
#4 Cross Cross +41.98%
#5 OVERTAKE OVERTAKE +41.07%
#6 Velvet Velvet +35.30%
#7 Black Phoenix Black Phoenix +33.82%
#8 Cap Cap +21.97%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.43%
#10 Bitway Bitway +11.98%
Coin of the day
Akedo Akedo
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
OncoCyte Corporation OncoCyte Corporation

OncoCyte Corporation

OCX
Classifica tra le azioni #38927
OncoCyte Corporation is a molecular diagnostics firm that conceptualizes,... OncoCyte Corporation is a molecular diagnostics firm that conceptualizes, refines, and brings to market its exclusive laboratory-developed tests aimed at identifying cancer in patients, serving both the United States and global markets. The company's portfolio features DetermaRx, a specialized molecular test for detecting early-stage adenocarcinoma in the lung, alongside DetermaIO, a unique proprietary assay that assesses gene expression. In addition to its diagnostic offerings, OncoCyte provides a suite of services including biomarker discovery, the design and development of new assays, and essential support for clinical trials. It also delivers various biomarker testing solutions specifically tailored for pharmaceutical companies. OncoCyte has established a collaborative agreement with Life Technologies Corporation. This partnership is geared towards the co-development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, which are designed for use with the Ion Torrent Genexus integrated sequencer and purification system. The corporation was founded in 2009 and its primary base of operations is situated in Irvine, California.
Prezzo delle azioni
$2.84
Ultima sincronizzazione: 2025-07-14
Capitalizzazione di mercato
$729.71K
Variazione (1 giorno)
-0.70%
Variazione (1 anno)
0.00%
Paese
US
Scambia OncoCyte Corporation (OCX)

Categoria

Healthcare
Ricavi di OncoCyte Corporation (OCX)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di OncoCyte Corporation, i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per OncoCyte Corporation da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE